We provide you with 20 years of free, institutional-grade data for RLMD stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RLMD. Explore the full financial landscape of RLMD stock.
| Reported Date | CIK | Ticker | Type |
|---|
Relmada Therapeutics, Inc(NASDAQ:RLMD) 
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of de...
Website: http://www.relmada.com
Founded: 2004
Full Time Employees: 6
CEO: Sergio Traversa
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
The information provided in this report about RLMD stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.